Market Overview

AstraZeneca Confirms Exploring Potential Strategic Options With Acerta Pharma

Related AZN
Market Reaction To Bristol-Myers' Mixed Clinical Results: 'A Little Excessive'
A Biotech Binary Event Playbook: How To Play Clovis And Tesaro Ahead Of Label Decision

Further to recent speculation, AstraZeneca (NYSE: AZN) confirms that it is exploring potential strategic options with Acerta Pharma BV. There can be no certainty that any transaction will ultimately be entered into, or as to the terms of any transaction.

The Company will make a further announcement if and when appropriate.

Dow Jones first reported a potential deal between the companies on Friday.

AstraZeneca shares closed down $0.22 on Friday, at $33.25.

Posted-In: News M&A Press Releases


Related Articles (AZN)

View Comments and Join the Discussion!